Essential Hypertension: Why Most High Blood Pressure Has No Single Cause, and What the SPRINT Trial Changed About Targets

The Scene

The patient in this scene is a composite. Names, ages, and circumstances are changed to protect privacy.

Diane is 52 years old and she has driven herself to the urgent care clinic in Champaign on a Tuesday afternoon because she has had a headache for three days. She does not think anything is wrong with her heart. She thinks she needs ibuprofen and sleep.

The nurse takes her blood pressure twice. She puts the cuff back on a third time. Then she asks Diane to lie down for five minutes and takes it again.

178 over 104.

Diane has never had a blood pressure reading above 135. She has had five readings in the last ten years, all at her annual physical. The last one was 128 over 82, which the doctor called “on the high side” and told her to watch her sodium.

She is not sure what 178 over 104 means. She knows it sounds bad. The urgent care physician refers her to cardiology and writes the words “hypertension, uncontrolled” on the referral form.

At the cardiology appointment two weeks later, Diane sits across from me with the referral in her hand and asks the question most of my patients ask when they first receive this diagnosis: “How could I not have known? How could my heart be doing this and I felt nothing?”

The answer to her question is the reason this article exists.

Hypertension is not a disease that announces itself. It does not produce chest pain, shortness of breath, or a visible wound. It works through pressure, steadily, against the walls of every artery in the body, over years and decades. The damage accumulates in silence. The first announcement is sometimes a stroke. Sometimes a heart attack. Sometimes a morning blood pressure reading that comes back 40 points higher than expected.

What It Is

The Plain-Language Definition

Blood pressure is the force your blood exerts against the walls of your arteries with every heartbeat. Every time your heart contracts, it pushes blood into the aorta, and that pulse of pressure travels through every artery in your body. Two numbers describe this pressure. The top number, the systolic, is the pressure when the heart is actively pumping. The bottom number, the diastolic, is the pressure when the heart is at rest between beats.

Essential hypertension is the condition of chronically raised blood pressure with no single identifiable medical cause. The word “essential” in this context does not mean important or necessary. It means idiopathic: arising from a complex interplay of genetics, environment, lifestyle, aging, and biology rather than from a single correctable lesion. This distinguishes it from secondary hypertension, which has a specific, identifiable cause.

The Medical Definition: What the Numbers Mean

The threshold for diagnosing hypertension has shifted twice in the past decade, and the shift matters.

From 2003 to 2017, the JNC 7 guideline defined hypertension as blood pressure at or above 140/90 mmHg. Normal was below 120/80. The range between 120-139 systolic or 80-89 diastolic was labeled “prehypertension.”

In 2017, the American College of Cardiology and the American Heart Association replaced JNC 7 with new guidelines that lowered the diagnostic threshold 5 / Solid . The new classification:

This reclassification effectively increased the percentage of US adults with hypertension from approximately 32% to approximately 46% overnight. The rationale was not pharmaceutical industry pressure, as some critics have alleged. The rationale was data: cardiovascular event rates begin to rise measurably at systolic pressures above 115 mmHg, and the SPRINT trial demonstrated that treating to a systolic target below 120 mmHg reduced cardiovascular events and all-cause mortality in high-risk patients 5 / Solid .

The 2017 guidelines also specify that hypertension diagnosis requires raised readings on at least two separate occasions. A single raised reading in an urgent care clinic is not a diagnosis.

Epidemiology: How Many People Have This

The scale of essential hypertension is genuinely difficult to communicate without the numbers sounding abstract, so consider them carefully.

Approximately 1.28 billion adults worldwide have hypertension 5 / Solid 01330-1). In the United States, approximately 116 million adults meet the 2017 ACC/AHA threshold for Stage 1 or Stage 2 hypertension. Of those, fewer than 25% have their blood pressure adequately controlled 5 / Solid .

The prevalence is not evenly distributed. Black Americans have the highest rates of hypertension of any racial group in the United States, with a prevalence approaching 58% in adults, significantly earlier age of onset, and higher rates of hypertensive end-organ damage compared to white Americans at the same blood pressure level 5 / Solid . The mechanisms for this racial disparity include salt sensitivity, sodium retention physiology, reduced access to care, social determinants of health, and potentially genetic factors, though the latter are not fully characterized.

The prevalence of hypertension also increases markedly with age. Fewer than 10% of adults under 40 have hypertension. By age 60, that figure exceeds 60%. By age 75, it approaches 80%. Aging produces vascular stiffening that drives systolic pressure up even when cardiac output is unchanged.

The Mechanism

Why Blood Pressure Rises

Understanding why blood pressure rises in essential hypertension requires understanding what determines blood pressure in the first place.

Blood pressure is the product of two things: how much blood the heart pumps per minute (cardiac output) and how much resistance the arteries offer to that flow (systemic vascular resistance). The relationship is Ohm’s law applied to fluid dynamics: pressure equals flow times resistance. Raise either flow or resistance without the other compensating, and pressure rises.

In essential hypertension, the dominant mechanism in most patients is increased systemic vascular resistance. The arteries are tighter than they should be. The specific biology of why they become and remain tighter involves at least four interlocking systems.

The Renin-Angiotensin-Aldosterone System

The renin-angiotensin-aldosterone system (RAAS) is the master regulator of blood pressure and sodium balance. When blood pressure drops or sodium delivery to the kidney falls, the juxtaglomerular cells of the kidney release renin. Renin cleaves a circulating protein, angiotensinogen, into angiotensin I. Angiotensin-converting enzyme (ACE) in the lungs converts angiotensin I into angiotensin II.

Angiotensin II does several things simultaneously. It constricts arterioles directly. It stimulates the adrenal gland to release aldosterone, which instructs the kidney to retain sodium and water. It increases sympathetic nervous system activity. All three effects raise blood pressure.

In essential hypertension, the RAAS is dysregulated. The system behaves as though blood pressure is perpetually too low, even when it is not. RAAS activity is particularly raised in sodium-sensitive forms of hypertension and in patients with chronic kidney disease, where reduced GFR triggers persistent RAAS activation 5 / Solid .

The Sympathetic Nervous System

The sympathetic nervous system drives blood pressure up via two routes: increasing heart rate and cardiac contractility (which raises cardiac output) and constricting peripheral arterioles (which raises systemic vascular resistance).

In essential hypertension, sympathetic nervous system tone is chronically raised. Studies using muscle sympathetic nerve activity recordings show that hypertensive patients have higher resting sympathetic activity than normotensive controls matched for age and weight 5 / Solid . Obesity amplifies this: adipose tissue produces leptin, which stimulates hypothalamic sympathetic drive. This is one of the mechanisms by which obesity causes hypertension.

Endothelial Dysfunction

The endothelium, the single-cell lining of every blood vessel, is not passive plumbing. It is an active signaling organ. Healthy endothelium produces nitric oxide (NO), a potent vasodilator. In hypertension, endothelial NO production is reduced and NO degradation is increased, largely because of oxidative stress.

Reduced NO means reduced vasodilation. Arterioles remain tonically constricted. This is both a consequence of raised blood pressure (the mechanical stress of high pressure damages endothelial cells) and a cause of it (damaged endothelium cannot produce the NO that would lower pressure). This bidirectional loop is why hypertension accelerates its own progression 5 / Solid .

Structural Vascular Changes

Over years, chronically raised pressure drives structural changes in small arteries and arterioles. The smooth muscle layer thickens (medial hypertrophy). The collagen-to-elastin ratio shifts toward collagen. The arteries become stiffer.

Stiffer arteries transmit pressure pulses poorly. Instead of absorbing the systolic ejection pulse and releasing it slowly through diastole, they transmit the pulse wave at higher velocity to the aorta and smaller vessels. Pulse wave velocity is now a validated marker of arterial stiffness and an independent predictor of cardiovascular events 5 / Solid .

This structural stiffening is the reason isolated systolic hypertension becomes increasingly common with age. When the aorta is stiff, systolic pressure rises and diastolic pressure falls, producing a widened pulse pressure. An elderly patient with systolic pressure of 165 mmHg and diastolic pressure of 72 mmHg has isolated systolic hypertension. The systolic pressure is the primary driver of their cardiovascular risk.

The Organ Damage Cascade

Raised blood pressure does not produce symptoms through direct sensation. It produces damage through mechanical stress, and that damage accumulates over years until a threshold is crossed.

Left Ventricular Hypertrophy. The left ventricle pumps against higher pressure in hypertension. Like any muscle, it responds by enlarging. Left ventricular hypertrophy (LVH) on echocardiogram is present in approximately 30% of hypertensive patients 5 / Solid . LVH is not benign compensatory remodeling. It is independently associated with increased risk of heart failure, atrial fibrillation, ventricular arrhythmia, and sudden cardiac death. LVH regression with blood pressure treatment is a validated surrogate endpoint that predicts improvement in cardiovascular outcomes 5 / Solid .

Chronic Kidney Disease. The kidney’s filtration units (glomeruli) are supplied by arteries under exactly the same pressure that damages coronary and cerebral arteries. Hypertension causes progressive glomerulosclerosis: thickening of the glomerular capillary walls and eventual fibrosis. This reduces GFR, which activates more RAAS, which raises blood pressure further. Hypertensive nephropathy is the second most common cause of end-stage renal disease in the United States after diabetic nephropathy 5 / Solid .

Lacunar Stroke and Cerebrovascular Disease. The small penetrating arteries of the brain, including the lenticulostriate arteries supplying the basal ganglia, are uniquely vulnerable to hypertension. They do not have the collateral circulation that larger cerebral territories have. When lipohyalinosis (a hypertension-specific vascular lesion) occludes a lenticulostriate artery, a small subcortical infarct results: a lacunar stroke. Lacunar strokes produce classic syndromes (pure motor hemiplegia, pure sensory syndrome, ataxic hemiparesis) but are often clinically silent if small. Accumulated silent lacunar infarcts produce vascular cognitive impairment 5 / Solid .

Hypertensive Retinopathy. The retinal arteries are directly visible through fundoscopy, making the retina the only organ where hypertensive vascular changes can be observed without invasive testing. Arteriovenous nicking (arteries compressing veins at crossing points), copper wiring, and flame hemorrhages all indicate end-organ damage. Grade III or IV retinopathy (hemorrhages, exudates, or papilledema) indicates a hypertensive emergency 5 / Solid .

How We Diagnose It

The Accurate Blood Pressure Measurement

Most of what is called “hypertension” in clinical practice is measured incorrectly. The error is usually not in the equipment. It is in the technique.

A blood pressure measurement is accurate only when:

• The patient has been seated quietly for at least five minutes before the reading
• The arm is supported at heart level
• The cuff is the correct size (a cuff too small gives falsely high readings; too large gives falsely low readings)
• The patient has not smoked, exercised, or consumed caffeine in the preceding 30 minutes
• The patient’s bladder is empty
• Talking does not occur during the measurement

Studies comparing blood pressure measured by patients themselves at home versus standard office measurement show that office readings average 5 to 10 mmHg higher than home readings in many patients 5 / Solid . This is white-coat hypertension.

White-Coat and Masked Hypertension

White-coat hypertension: raised readings in the office, normal readings outside the office. Affects approximately 15-20% of adults who are told they have hypertension. The cardiovascular risk of white-coat hypertension is intermediate between normal and sustained hypertension, not negligible 5 / Solid .

Masked hypertension: normal readings in the office, raised readings outside. Affects approximately 10-15% of adults. Because it is not detected in standard office practice, masked hypertension carries higher cardiovascular risk than white-coat hypertension, roughly equivalent to sustained hypertension 5 / Solid .

The gold standard for resolving the distinction is ambulatory blood pressure monitoring (ABPM): a device worn for 24 hours that records blood pressure automatically every 15-30 minutes during the day and every 30-60 minutes at night. ABPM provides daytime average, nighttime average, and the dipping pattern (the normal nocturnal fall in blood pressure of 10-20%). Non-dippers and reverse-dippers (whose blood pressure rises at night) have significantly raised cardiovascular risk beyond their daytime readings 5 / Solid .

Who Gets ABPM

Current ACC/AHA guidelines recommend ABPM or home BP monitoring to confirm the diagnosis before initiating antihypertensive therapy in patients who appear to have Stage 1 hypertension on office readings. ABPM is particularly useful in:

• Patients with suspected white-coat or masked hypertension
• Patients with resistant hypertension (to confirm true resistance)
• Patients with atrial fibrillation (automatic oscillometric devices are unreliable in AF)
• Evaluation of nocturnal hypertension and dipping pattern
• Assessment of blood pressure variability

In central Illinois, ABPM is available through Carle Foundation Hospital in Urbana and through OSF Healthcare in Peoria and Springfield. In Chicago, Northwestern Medicine and Rush University Medical Center maintain active hypertension specialty programs. For rural patients who cannot access ABPM, validated home blood pressure monitors provide a reasonable surrogate when proper technique is used.

Laboratory Evaluation at Diagnosis

When hypertension is first diagnosed, a baseline evaluation is standard:

• Basic metabolic panel (electrolytes, creatinine, GFR) to assess kidney function and detect hypokalemia that might suggest secondary cause
• Urinalysis with microscopy (proteinuria suggests end-organ damage)
• Fasting lipid panel and glucose (hypertension rarely exists alone; the metabolic cluster is the rule)
• 12-lead ECG (left ventricular hypertrophy by voltage criteria, LVH repolarization changes)
• Thyroid function (hyperthyroidism and hypothyroidism both affect blood pressure)

Echocardiography is not mandatory for all newly diagnosed hypertensive patients, but it provides the most sensitive assessment of LVH and diastolic function and is appropriate when there is clinical suspicion of end-organ damage or unexplained symptoms.

The Evidence

The SPRINT Trial: What Intensive Blood Pressure Control Actually Showed

The Systolic Blood Pressure Intervention Trial (SPRINT) is the most influential hypertension trial of the past two decades. It randomized 9,361 non-diabetic adults with systolic blood pressure of 130 mmHg or higher and at least one additional cardiovascular risk factor to intensive treatment (systolic target below 120 mmHg) versus standard treatment (systolic target below 140 mmHg) 5 / Solid .

The trial was stopped early, after 3.26 years, because the difference in outcomes was large enough that the data safety monitoring board determined it would be unethical to continue. The intensive group had:

• 25% lower rate of the primary outcome (MI, ACS, stroke, HF, or cardiovascular death): HR 0.75 (95% CI 0.64-0.89)
• 27% lower rate of all-cause mortality: HR 0.73 (95% CI 0.60-0.90)
• 38% lower rate of cardiovascular death

The cost: higher rates of serious adverse events in the intensive group, specifically hypotension (2.4% vs 1.4%), syncope (2.3% vs 1.7%), acute kidney injury (4.1% vs 2.5%), and electrolyte abnormalities. These are real and not trivial.

Important SPRINT caveat: SPRINT excluded diabetics and patients with prior stroke. The diabetic equivalent, ACCORD-BP, showed no benefit from intensive systolic lowering below 120 mmHg in type 2 diabetics 5 / Solid . The SPRINT benefit cannot be extrapolated to diabetic patients.

How SPRINT was measured matters: SPRINT used unattended automated office blood pressure measurement, which produces readings approximately 5-10 mmHg lower than attended office measurement. This means the trial’s 120 mmHg target corresponds to approximately 130 mmHg by conventional office measurement. When clinicians try to achieve what SPRINT achieved, they should target approximately 130/80 mmHg by standard office measurement 5 / Solid .

Older Foundation Evidence: The Framingham, HOT, and ALLHAT Trials

The Framingham Heart Study established the linear relationship between blood pressure and cardiovascular risk in long-term prospective data going back to 1948. The landmark observation: each 20 mmHg increase in systolic pressure or 10 mmHg increase in diastolic pressure doubles the risk of cardiovascular events across the blood pressure range from 115/75 to 185/115 mmHg 5 / Solid 11911-8).

The HOT trial (Hypertension Target Treatment) randomized 18,790 hypertensive patients to different diastolic targets (below 90, 85, or 80 mmHg) and found no significant difference in outcome between groups in the overall population, but significant benefit in diabetics from more intensive treatment 5 / Solid 04311-6).

ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial) randomized 42,418 hypertensive patients to chlorthalidone (a thiazide diuretic), amlodipine (a calcium channel blocker), or lisinopril (an ACE inhibitor). Chlorthalidone was not inferior to the other agents on the primary combined endpoint and was superior for heart failure 5 / Solid . This trial established the thiazide diuretic as a first-line agent rather than the expensive branded drugs that had dominated prescribing.

Blood Pressure Reduction and Stroke Prevention

The evidence for blood pressure reduction and stroke prevention is among the strongest in all of cardiovascular medicine. A meta-analysis of 61 prospective observational studies (1 million adults, 12.7 million person-years) found that each 10 mmHg reduction in systolic blood pressure is associated with approximately 30% lower stroke risk 5 / Solid 11911-8). This is not a modest effect. This is the strongest dose-response relationship in preventive cardiology.

Sex Differences in Hypertension

Women develop hypertension approximately a decade later than men on average, with rates rising sharply after menopause, when the cardioprotective effects of estrogen on vascular compliance diminish 5 / Solid . However, women with hypertension have worse outcomes than men at similar blood pressure levels for reasons that are not fully understood. This disparity is most pronounced in hypertensive heart disease and hypertension-related heart failure with preserved ejection fraction, where women predominate 5 / Solid .

Pregnancy-related hypertension deserves special mention. Preeclampsia (hypertension with proteinuria after 20 weeks gestation) is not only an obstetric emergency; it is a cardiovascular risk marker. Women with a history of preeclampsia have approximately double the lifetime risk of hypertension, stroke, and ischemic heart disease compared to women with uncomplicated pregnancies 5 / Solid . This history should be documented in every cardiovascular risk assessment.

The Patient Experience

What Hypertension Feels Like (Usually: Nothing)

The cardinal feature of hypertension from the patient’s perspective is its invisibility. The pressure can be 180/110 for years without a symptom. The headache that most patients associate with high blood pressure is not reliably caused by hypertension at moderate levels; it is associated with very high levels and hypertensive emergencies, but not with the blood pressure readings most hypertensive patients carry day to day 5 / Solid .

This invisibility creates a specific psychological problem: it makes adherence to medication difficult. Why take a pill daily when you feel fine and the pill causes side effects? The gap between feeling fine and being at risk is abstract. Closing that gap is one of the primary jobs of the clinician caring for a hypertensive patient.

The Side Effect Profile of Antihypertensive Medications

ACE inhibitors (lisinopril, enalapril, ramipril): The most common side effect is a dry, persistent cough that occurs in 5-20% of patients. The mechanism is accumulation of bradykinin in the airways. Angioedema is rare but serious (approximately 0.1-0.3%). ACE inhibitors are contraindicated in pregnancy (fetotoxic in second and third trimesters).

Angiotensin receptor blockers (ARBs) (losartan, valsartan, olmesartan): Similar efficacy to ACE inhibitors, without the cough, because they block the angiotensin II receptor rather than inhibiting ACE. They are the preferred alternative for patients who cannot tolerate ACE inhibitors due to cough.

Thiazide diuretics (hydrochlorothiazide, chlorthalidone): First-line in most guidelines. Common metabolic side effects include hypokalemia (can be managed with dietary potassium or potassium supplementation), hyperuricemia (can precipitate gout in susceptible patients), and modest glucose intolerance. Chlorthalidone has a longer duration of action and better 24-hour coverage than hydrochlorothiazide 5 / Solid .

Calcium channel blockers (amlodipine, diltiazem, verapamil): Amlodipine is a dihydropyridine CCB used for blood pressure. Common side effects include ankle edema (most common, approximately 10-15% at standard doses) and facial flushing. Non-dihydropyridine CCBs (diltiazem, verapamil) also reduce heart rate and are not combined with beta-blockers.

Beta-blockers (metoprolol, carvedilol, atenolol): Not first-line for uncomplicated hypertension per current guidelines, but used when there is coexisting heart failure, angina, atrial fibrillation rate control, or post-MI indication. Common side effects include fatigue, exercise intolerance (blunting of peak heart rate), cold extremities, and sexual dysfunction.

The Adherence Problem

In large real-world registries, fewer than 50% of patients prescribed antihypertensive medication are adherent at one year 5 / Solid . The reasons are predictable: asymptomatic disease, side effects, cost, complexity of regimen, healthcare system navigation.

Several evidence-based strategies improve adherence: single-pill combinations (one tablet instead of three), pharmacist-led telemonitoring programs, home blood pressure measurement with feedback, and culturally adapted education. The most powerful predictor of medication adherence is whether the patient actually understands why they are taking the medication, not just that they have been told to.

Decisions and Trade-Offs

Who Should Be Treated With Medication

The 2017 ACC/AHA guidelines recommend lifestyle modification alone for Stage 1 hypertension (130-139/80-89 mmHg) when the 10-year ASCVD risk (calculated by the Pooled Cohort Equations) is below 10%. Medication is added when:

• ASCVD risk is 10% or higher with Stage 1 hypertension
• Blood pressure meets Stage 2 criteria (140/90 or higher) regardless of ASCVD risk
• Hypertensive end-organ damage is already present

This risk-stratified approach means that a 35-year-old with a blood pressure of 134/84 and no other risk factors does not necessarily need medication. A 62-year-old with the same blood pressure plus diabetes and a smoking history does. This is not bureaucratic complexity; it is the application of absolute risk thinking to clinical decision-making.

Lifestyle Modifications: How Much They Actually Work

Lifestyle modifications are not token gestures before the real treatment begins. They have quantified blood pressure reduction effects:

These figures come from the DASH trial 5 / Solid and subsequent meta-analyses. The DASH diet achieves blood pressure reductions comparable to a single antihypertensive medication. In patients with Stage 1 hypertension and no compelling indication for immediate pharmacotherapy, a 3-to-6-month trial of intensive lifestyle modification is a reasonable and evidence-supported approach.

The Intensification Decision

Clinicians and patients often negotiate around the intensification of antihypertensive therapy. A blood pressure of 142/88 on one medication is not dramatically different from 138/86. But the cumulative effect of carrying blood pressure 5-10 mmHg above goal over 10 years is measurable in cardiovascular events. The evidence shows treating to goal rather than treating to good-enough 5 / Solid .

Which Medication First

For most patients with uncomplicated essential hypertension and no other comorbidities, the current first-line choices are:

1. Thiazide or thiazide-like diuretic (chlorthalidone preferred over HCTZ for 24-hour coverage)
2. Long-acting dihydropyridine calcium channel blocker (amlodipine)
3. ACE inhibitor or ARB (particularly beneficial with CKD or diabetes)

In Black Americans, ACE inhibitors and ARBs as monotherapy are less effective due to low-renin physiology; thiazides and CCBs provide better first-line blood pressure control 5 / Solid . This is not a contraindication to RAAS blockade; it is a reason to combine rather than substitute.

The Access Reality in Central Illinois

Carle Foundation Hospital in Urbana operates a hypertension specialty clinic. OSF Healthcare systems in Peoria and Bloomington-Normal provide hypertension management. For patients in rural Douglas, Moultrie, and Coles counties who cannot access specialty care, primary care-based hypertension management with home BP monitoring and telepharmacy support has been shown to achieve blood pressure control rates equivalent to in-person specialty care when protocols are followed 5 / Solid , and bring that log to your next appointment. This one step closes the gap between white-coat effect and true blood pressure.

For patients whose ABPM or home log confirms hypertension: the goal is blood pressure below 130/80 mmHg, achieved first with lifestyle and then with medication if needed. The SPRINT data on intensive control below 120 mmHg systolic are relevant primarily for patients with high ASCVD risk who can tolerate the medication burden without excessive side effects.

A structured cardiovascular assessment and programs both include blood pressure profiling as a core component of the initial evaluation. A patient who arrives knowing their blood pressure, their lipid panel, and their family history is a patient who can have a real conversation about their risk instead of a visit built around a blood pressure measurement that is already three years old.

Hypertension is not inevitable. It is not a consequence of getting older that medicine cannot address. The 25% relative risk reduction in cardiovascular events with intensive treatment translates, across a population of 116 million hypertensive Americans, to tens of thousands of preventable deaths per year. That is the arithmetic behind the clinical priority.

Extended Evidence Review: The Major Hypertension Outcome Trials

SPRINT: The 120 mmHg Target Debate

The SPRINT (Systolic Blood Pressure Intervention Trial) trial remains the most influential and debated hypertension outcome trial of the past decade. SPRINT enrolled 9,361 non-diabetic adults at high cardiovascular risk (established CVD, CKD, 10-year cardiovascular disease risk above 15%, or age above 75) and randomized them to intensive treatment (target systolic BP below 120 mmHg) or standard treatment (target below 140 mmHg). 5 / Solid The trial was stopped early at 3.26 years due to significant benefit in the intensive group:

• Primary outcome (MI, ACS, stroke, heart failure, or CV death): HR 0.75 (25% relative reduction)
• All-cause mortality: HR 0.73 (27% relative reduction)
• Cardiovascular death: HR 0.57 (43% relative reduction)

The early stopping raises the standard concern about overestimation of treatment effects. Nevertheless, the primary endpoint was convincing with narrow confidence intervals, and SPRINT has substantially influenced the downward revision of blood pressure targets in the 2017 ACC/AHA guidelines.

The ACCORD comparison: ACCORD enrolled diabetic patients (specifically excluded from SPRINT) and randomized them to the same target comparison (below 120 vs below 140 mmHg systolic). ACCORD found no significant difference in the primary cardiovascular endpoint for the BP intervention arm (though a non-significant trend favoring intensive treatment for stroke). The absence of SPRINT-like benefit in diabetics was attributed to the different cardiovascular risk profile of diabetic patients and the blunting of BP-related benefit by metabolic disease. 5 / Solid

The SPRINT-MIND sub-study (cognitive outcomes): A pre-specified sub-study of SPRINT found that intensive BP lowering significantly reduced the combined endpoint of mild cognitive impairment and dementia (HR 0.85, 95% CI 0.74-0.97) over 5.1 years of follow-up. 4 / Promising This finding adds a neurological dimension to the cardiovascular argument for intensive BP control: preservation of cognitive function in older adults as a treatment goal.

The STEP Trial: STEP (Strategy of Blood Pressure Intervention in the Elderly Hypertensive Patients) enrolled 8,511 Chinese adults aged 60-80 with systolic BP 140-190 mmHg and randomized them to intensive (systolic 110-130 mmHg) versus standard (130-150 mmHg) treatment. 5 / Solid The intensive group had 26% lower primary cardiovascular events (HR 0.74, 95% CI 0.60-0.92), consistent with SPRINT in an older population. STEP provides corroborating evidence that intensive BP control is beneficial across diverse populations.

ALLHAT: Drug Choice Matters Less Than BP Control

The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) enrolled 33,357 high-risk hypertensive patients and randomized them to chlorthalidone, amlodipine, lisinopril, or (a fourth arm discontinued early) doxazosin. 5 / Solid The primary finding was that chlorthalidone (thiazide-like diuretic) was equivalent or superior to amlodipine and lisinopril for preventing fatal coronary heart disease and nonfatal MI, and was significantly better than doxazosin for heart failure prevention.

Key lessons from ALLHAT:

1. Thiazide diuretics remain first-line antihypertensive agents despite their metabolic effects (modest hyperglycemia, hypokalemia): the cardiovascular outcomes are equivalent or superior to newer agents
2. Drug class choice matters for specific organ protection (e.g., ACE inhibitors for CKD and diabetes, beta-blockers post-MI, aldosterone antagonists for heart failure) but less so for primary cardiovascular prevention in the absence of these specific indications
3. Blood pressure reduction itself: regardless of drug used: is the primary mechanism of benefit

Pharmacological Principles: Five Drug Classes in Detail

ACE Inhibitors: Block angiotensin-converting enzyme, preventing the conversion of angiotensin I to angiotensin II. Reduce afterload, reduce aldosterone secretion, and prevent RAAS-mediated organ damage independently of their blood pressure effect (demonstrated in the HOPE trial with ramipril reducing cardiovascular events in patients without hypertension). 5 / Solid Adverse effects: dry cough (bradykinin accumulation, 5-15% of patients; much higher in East Asian patients, approximately 40%), hyperkalemia (particularly in CKD), angioedema (rare but serious; may occur up to years after initiation). Contraindicated in pregnancy (teratogenic).

ARBs: Block the AT1 receptor directly, preventing angiotensin II from producing its vasoconstriction, aldosterone stimulation, and cellular growth promotion. Comparable cardiovascular efficacy to ACE inhibitors. Preferred when ACE inhibitor cough occurs. The combination of ACE inhibitor plus ARB provides minimal additional benefit and is associated with increased adverse effects (ONTARGET trial, 2008). Contraindicated in pregnancy.

Calcium Channel Blockers (CCBs): Dihydropyridines (amlodipine, nifedipine) block L-type calcium channels in vascular smooth muscle and cardiac muscle, producing peripheral vasodilation and modest negative inotropism. Excellent for isolated systolic hypertension in the elderly, effective in Black patients (in whom RAAS-targeted drugs are often less effective as monotherapy). Adverse effect: ankle edema (accumulates with higher doses; mechanism is precapillary vasodilation without proportional postcapillary dilation). Non-dihydropyridines (diltiazem, verapamil) also reduce heart rate: useful when rate control is desired but contraindicated in heart failure with reduced ejection fraction.

Thiazide and Thiazide-Like Diuretics: HCTZ and chlorthalidone block Na-Cl cotransport in the distal convoluted tubule, reducing sodium reabsorption. Chlorthalidone has a much longer half-life than HCTZ (45-60 hours vs 8-15 hours) and provides more consistent 24-hour blood pressure reduction per dose. Multiple analyses comparing equivalent doses find chlorthalidone more effective than HCTZ for cardiovascular event reduction. Adverse effects: hypokalemia, hyponatremia, hyperglycemia (modest), hyperuricemia and gout, sexual dysfunction in men.

Beta-Blockers: Reduce heart rate and cardiac output through beta-1 adrenergic blockade; some agents also reduce peripheral vascular resistance through alpha-1 blockade (labetalol, carvedilol) or vasodilation through other mechanisms (nebivolol through NO release). Beta-blockers are not first-line for uncomplicated hypertension (meta-analyses show slightly worse cardiovascular outcomes compared to other classes in primary prevention, particularly for stroke prevention), but are essential for specific indications: post-MI, heart failure with reduced EF, certain arrhythmias, and symptomatic coronary artery disease.

Extended Patient Experience: The 60-Year-Old Who Finally Asks Why

James’s scenario in the Scene section: newly diagnosed Stage 2 hypertension at age 60: is extraordinarily common. The statistics are clear: at age 60 in the United States, the majority of adults have at least Stage 1 hypertension by 2017 ACC/AHA criteria, and a substantial proportion are unaware. The question “why didn’t anyone tell me sooner?” deserves an honest answer.

The structural reasons for late hypertension diagnosis in the United States:

1. Infrequent primary care contact: Many working-age adults go years without preventive care visits. Annual physicals are not universal in US health insurance structures; high-deductible plans discourage preventive visits.
2. Measurement variability: A single raised reading at an urgent care visit for an acute illness may not be followed up. The diagnosis requires confirmation, which requires a return visit.
3. White-coat effect: Patients with anxiety-associated office hypertension may have masked hypertension identified only with home monitoring: which may not be recommended or followed through.
4. Asymptomatic nature: Hypertension is the prototypical silent disease. Without a symptom driving the patient to seek care, decades can pass undetected.

This clinical approach at Carle Foundation Hospital includes hypertension screening as a standard component of a cardiovascular audit: blood pressure on three separate occasions using validated technique, home BP monitoring for 7 days to obtain an average, and assessment of end-organ damage (urinalysis, serum creatinine, ECG for LVH) when Stage 2 hypertension is identified.

Illinois Context: Hypertension Disparities and Community Programs

Hypertension prevalence and cardiovascular mortality from hypertension-related disease show significant geographic variation within Illinois. Rural Illinois counties (particularly in southern and western Illinois) have higher rates of uncontrolled hypertension and higher rates of hypertension-related stroke than urban Cook County. 5 / Solid

The American Heart Association’s Target:BP program, active in Illinois community health centers, provides technical assistance for standardized blood pressure measurement and treatment protocols. Several Federally Qualified Health Centers in rural Champaign County (Carle’s service area) and Piatt County participate in Target:BP.

The disparity between Black and white hypertension prevalence and outcomes in Illinois mirrors national patterns: Black adults have approximately 10-percentage-point higher hypertension prevalence and significantly higher rates of end-stage renal disease from hypertensive nephrosclerosis compared to white adults in the same income bracket. Community-level interventions addressing access to antihypertensive medications, affordable healthy food, and safe exercise environments are as important as clinical management for addressing the hypertension burden in Champaign-Urbana’s diverse population.

The Signal Check is fifteen questions mapping the cardiovascular risk pattern across the physiological domains most commonly missed in standard screenings. It produces a specific starting point for your next clinical conversation.